TMCnet News

Premier Biomedical, Inc. Signs Deal with Consultant Team in Brazil to Arrange Possible JV Partnerships for Growth
[July 28, 2015]

Premier Biomedical, Inc. Signs Deal with Consultant Team in Brazil to Arrange Possible JV Partnerships for Growth


Premier Biomedical, Inc. (OTCQB: BIEI) announced that they have agreed to terms whereby FBROCCO Assessoria Empresarial Ltda, will act in Premier's interests in locating and securing financing and possible joint venture partners in Brazil to develop and market medications and devices being developed by Premier for treating various disease, such as fibromyalgia, MS, and cancer.

Francisco Brocco, Managing Partner of FBROCCO, said, "I am looking forward to working with Premier Biomedical to bring their innovative medical treatments to the Brazilian people as well as to all of South America. I see this as a very positive move for all concerned."

William A. Hartman, President and CEO of Premier Biomedical, stated, "We believe Mr. Brocco and his staff have the drive and connections to find the most suitable joint venture partner for us in Brazil, to successfully bring our products quickly and safely to the entire South American market as a first step. This alliance will provide badly needed revenue in the short term to finance the further development of our extensive pipeline of new products for the market."

Mr. Hrtman will be traveling to Brazil in the very near future to meet with joint venture candidates and intends to sign a framework agreement with a potential partner.



About FBROCCO Brazil Healthcare Market Advisors.

FBROCCO is a management consulting focused on helping healthcare companies implement the right local strategies, tactics and tools required to create a sustainable competitive advantage in the dynamic BrazilĀ“s fast-growing healthcare market.


About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.


[ Back To TMCnet.com's Homepage ]